These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8648206)
61. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187 [TBL] [Abstract][Full Text] [Related]
62. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Nielsen H; Kvinesdal B; Benfield TL; Lundgren JD; Konradsen HB Scand J Infect Dis; 1998; 30(6):597-601. PubMed ID: 10225389 [TBL] [Abstract][Full Text] [Related]
63. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180 [TBL] [Abstract][Full Text] [Related]
64. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Breiman RF; Keller DW; Phelan MA; Sniadack DH; Stephens DS; Rimland D; Farley MM; Schuchat A; Reingold AL Arch Intern Med; 2000 Sep; 160(17):2633-8. PubMed ID: 10999977 [TBL] [Abstract][Full Text] [Related]
65. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. Giebink GS; Koskela M; Vella PP; Harris M; Le CT J Infect Dis; 1993 Feb; 167(2):347-55. PubMed ID: 8421168 [TBL] [Abstract][Full Text] [Related]
66. Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines. Petrasch S; Kühnemund O; Reinacher A; Uppenkamp M; Reinert R; Schmiegel W; Lütticken R; Brittinger G Clin Diagn Lab Immunol; 1997 Nov; 4(6):635-8. PubMed ID: 9384280 [TBL] [Abstract][Full Text] [Related]
67. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665 [TBL] [Abstract][Full Text] [Related]
68. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Coughlin RT; White AC; Anderson CA; Carlone GM; Klein DL; Treanor J Vaccine; 1998 Nov; 16(18):1761-7. PubMed ID: 9778753 [TBL] [Abstract][Full Text] [Related]
70. Evaluation of antibody responses to pneumococcal vaccines with ELISA and opsonophagocytic assay. Kim KH; Seoh JY J Korean Med Sci; 1999 Oct; 14(5):475-9. PubMed ID: 10576141 [TBL] [Abstract][Full Text] [Related]
71. Impaired immunity to pneumococcal polysaccharide antigens in children with human immunodeficiency virus infection immunized with pneumococcal vaccine. Peters VB; Diamant EP; Hodes DS; Cimino CO Pediatr Infect Dis J; 1994 Oct; 13(10):933-4. PubMed ID: 7854897 [No Abstract] [Full Text] [Related]
72. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Opravil M; Fierz W; Matter L; Blaser J; Lüthy R Clin Exp Immunol; 1991 May; 84(2):185-9. PubMed ID: 2025948 [TBL] [Abstract][Full Text] [Related]
73. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. Rubins JB; Puri AK; Loch J; Charboneau D; MacDonald R; Opstad N; Janoff EN J Infect Dis; 1998 Aug; 178(2):431-40. PubMed ID: 9697723 [TBL] [Abstract][Full Text] [Related]
74. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Konradsen HB; Rasmussen C; Ejstrud P; Hansen JB Epidemiol Infect; 1997 Oct; 119(2):167-74. PubMed ID: 9363015 [TBL] [Abstract][Full Text] [Related]
75. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485 [TBL] [Abstract][Full Text] [Related]
76. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327 [TBL] [Abstract][Full Text] [Related]